Loading...
Loading...
HCM| Name | Value |
|---|---|
| Revenues | 266.4M |
| Cost of Revenue | 104.2M |
| Gross Profit | 162.3M |
| Operating Expense | 76.2M |
| Operating I/L | 55.8M |
| Other Income/Expense | 30.3M |
| Interest Income | 0.1M |
| Pretax | 86.1M |
| Income Tax Expense | 1.4M |
| Net Income/Loss | 84.3M |
HUTCHMED (China) Limited is a biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases. The company operates in the Oncology/Immunology and Other Ventures segments, focusing on developing a range of inhibitors for various cancers and solid tumors. Its products include Savolitinib, Fruquintinib, Surufatinib, HMPL-523, Tazemetostat, and several other inhibitors targeting specific types of cancer. HUTCHMED generates revenue through the development and commercialization of these innovative therapies, as well as through collaboration agreements with leading pharmaceutical companies in the industry.
